Optic Neuritis and Multiple Sclerosis, What You Should Know
Optic neuritis (also called demyelinating optic neuritis) is inflammatory demyelination of the optic nerve. Symptoms include vision loss (which can be permanent in some cases), seeing flashing or flickering lights, eye pain with eye movement, and loss ...
eMaxHealth - Thu, 30 Apr 2015 14:55

Antiseizure Drug Helps Optic Neuritis in Multiple Sclerosis
The relationship between seizures, optic neuritis, and multiple sclerosis may seem difficult to fathom, but the results of a new study shed some light on the subject. It appears that the common antiseizure drug called phenytoin has the ability to help ...
eMaxHealth - Thu, 23 Apr 2015 07:14

Seizure Medication Reduced Optic Neuritis In Multiple Sclerosis
Medical Research News and Interviews on MedicalResearch.com (blog) - Thu, 23 Apr 2015 12:52

Epilepsy Drug May Treat Eye Complications in Patients With MS
Multiple Sclerosis News Today - Wed, 22 Apr 2015 08:37

Repurposed drug an eye opener for MS
6minutes - Wed, 22 Apr 2015 21:41

Global optic neuritis therapeutic pipeline market review and comparative ...
Complete report on H1 2015 pipeline review of Optic Neuritis with 22 market data tables and 13 figures, spread across 60 pages is available at http://www.rnrmarketresearch.com/optic-neuritis-pipeline-review-h1-2015-market-report.html . (This is a ...
WhaTech - Thu, 23 Apr 2015 14:45

Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for ...
... with KEYTRUDA: exfoliative dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial seizures arising in a patient with inflammatory foci in brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic neuritis, and ...
EIN News (press release) - Fri, 22 May 2015 04:03

Late post-transplant anti-aquaporin-4 Ab-positive optic neuritis in a patient ...
Seropositivity for anti-aquaporin-4 Abs (AQP-4-IgG) marks severe forms of optic neuritis (ON), which are part of the so-called neuromyelitis optica spectrum disorders (NMOSD), and can remain isolated or evolve into the complete phenotype of the ...
Nature.com - Mon, 27 Apr 2015 07:21

Q&A With Diego Cadavid, MD, FAAN, of Biogen: Anti-Lingo-1 for Optic Neuritis ...
Diego Cadavid, MD, FAAN, from Biogen International discussed the effects of Anti-LINGO-1 in the treatment of Acute Optic Neuritis and the results of the RENEW Trial during the American Academy of Neurology's annual meeting in Washington DC.
HCPLive - Tue, 28 Apr 2015 09:19

Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Biogen (NASDAQ: BIIB) announced detailed results from the Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis (AON) – the first clinical study to demonstrate remyelination (the formation of new ...
Business Wire (press release) - Tue, 14 Apr 2015 13:03

Biogen Reports New Data from Acute Optic Neuritis Study
Zacks.com - Wed, 15 Apr 2015 14:11

Biogen Reports New Data from Acute Optic Neuritis Study - Analyst Blog
Nasdaq - Wed, 15 Apr 2015 16:18

Biogen Idec anti-LINGO-1 data in acute optic neuritis whet appetites for more
Disclosure of top-line data on Biogen Idec Inc.'s anti-LINGO-1 monoclonal antibody (MAb), BIIB033, in acute optic neuritis (AON) so captivated the analyst community that they might have been mistaken for scrutinizing a grand slam emerging from a ...
BioWorld Online - Thu, 08 Jan 2015 18:37

Biogen Reveals Positive Data from Acute Optic Neuritis Study
Zacks.com - Fri, 09 Jan 2015 13:33

Biogen's Nerve Repair Drug Yields Mixed Results in Key Eye Trial
TheStreet.com - Thu, 08 Jan 2015 05:35

Limited Success With Myelin Rebuilder in Optic Neuritis
MedPage Today - Thu, 08 Jan 2015 10:11

Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial ...
FierceBiotech - Thu, 08 Jan 2015 04:22

Biogen shares fall after optic nerve study results seen as mixed
Yahoo News - Thu, 08 Jan 2015 05:12

1  2  3  4  5  6  7  8    ->

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014